Table 2 Characteristics of included studies for neoadjuvant chemotherapy
Study | Year | No. of cases | Classification of pathologic response | Definition of pCR | NACT regimens | Surgery after NACT |
|---|---|---|---|---|---|---|
Agarwal | 2017 | 38 | Miller-Payne | Miller-Payne grade V | CEF, CAF, CEF + DE, DE, DC + Herceptin, DEC | Modified radical mastectomy or wide local excision |
Atuegwu | 2013 | 28 | – | No residual invasive cancer in the breast or lymph nodes | AC + taxol, Taxotere, Taxol + cisplatin ± everolimus, Trastuzumab +carboplatin + ixabepilone, Trastuzumab, and lapatinib | NR |
Belli | 2011 | 51 | Mandard’s TRG criteria | TRG 1 | FEC, AT, TAC, and TC ± carboplatinum or trastuzumab | Surgery |
Bufi | 2014 | 225 | Mandard’s TRG criteria | TRG 1 | Doxorubicin and cyclophosphamide, and taxanes-based regimens | Breast-conserving and nipple sparing surgery; Surgical excision |
Bufi | 2015 | 225 | Mandard’s TRG criteria | TRG 1 | Doxorubicin, taxane, and cyclophosphamide-based regimens | Breast-conserving and nipple sparing surgery; Surgical excision |
Che | 2016 | 36 | Miller-Payne | Miller-Payne grade V | Paclitaxel with epirubicin or paclitaxel with carboplatin | Breast-conserving surgery with axillary nodal clearance or modified radical mastectomy. |
Fangberget | 2010 | 31 | – | Absence of invasive cancer | 5-fluoro-uracil, epirubicin and cyclophosphamide | Surgery |
Fujimoto | 2013 | 56 | Japanese Breast Cancer Society criteria | Necrosis or disappearance of all tumor cells | Adriamycin and cyclophosphamide, paclitaxel, 5-fluorouracil, epirubicin, and cyclophosphamide, paclitaxel | Lumpectomy or mastectomy |
Li | 2011 | 32 | – | Absence of invasive cancer on breast tumor and lymph nodes | Docetaxel and epirubicin | Breast-conserving surgery or modified radical mastectomy |
Li | 2015 | 42 |  | No invasive tumor in the breast | DOX + Cyc + Tax, Cis/Tax±RAD001, Tra + Car, Tra/Car/Her, Tax | Mastectomy or lumpectomy |
Luo | 2014 | 71 | Miller-Payne | Miller-Payne grade V | NR | NR |
Mani | 2013 | 28 | – | No residual tumor in the breast or lymph nodes | Adriamycin/cytoxan, taxol/trastuzumab; docetaxel, carboplatin, and trastuzumab; or lapatinib and trastuzumab | Surgery |
Park | 2010 | 53 | – | Absence of recognizable invasive tumor cells (DCIS may have been present) | Docetaxel and doxorubicin with granulocyte colony–stimulating factor | Modified radical mastectomy or breast-conserving surgery |
Park | 2011 | 34 | – | No residual malignancy and no sign of cancer cells; no residual invasive cancer and DCIS present | Doxorubicin and docetaxel; paclitaxel, gemcitabine and trastuzumab | Modified radical mastectomy or breast-conserving surgery |
Richard | 2013 | 118 | Chevalier-Sataloff classifications | Chevalier class 1, Sataloff A | Epirubicin and cyclophosphamide, docetaxel; epirubicin and cyclophosphamide, trastuzumab | Mastectomy or breast-conservative surgery |
Sharma | 2009 | 56 | – | No residual tumor | CEF; PþE | NR |
Shin | 2012 | 90 | – | No residual tumor or absence of invasive cancer, but presence of DCIS | Doxorubicin and cyclophosphamide; cyclophosphamide and docetaxel; adriamycin plus docetaxel; 5-fluorouracil, epirubicin and cyclophosphamide; trastuzumab plus paclitaxel | Surgery |
Weis | 2015 | 33 | – | No residual tumor in the breast or nodes | Paclitaxel, carboplatin, and trastuzumab; doxorubicin and cyclophosphamide, paclitaxel; cisplatin and paclitaxel ± everolimus | NR |
Woodhams | 2010 | 69 | – | No residual disease or no invasive cancer or DCIS present | Anthracycline and cyclophosphamide, paclitaxel | Quadrantectomy or mastectomy |
Xu | 2017 | 174 | – | No residual tumor in the breast or nodes | Cyclophosphamide + epirubicin and tatotere | NR |